http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005075392-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D295-185 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-30 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D295-185 |
| filingDate | 2003-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_83e8e5d9f50f704840ac021c1c327dac http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e7a0c3870f3644112173b39b09e425bf |
| publicationDate | 2005-04-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2005075392-A1 |
| titleOfInvention | Novel pharmaceuticals |
| abstract | The invention relates to NEP inhibitors for treating cardiovascular disorders. Preferred NEP inhibitors are compounds of formula (I) wherein R 1 is C 1 -C 6 alkyl, C 1 -C 6 alkoxyC 1 -C 3 alkyl or C 1 -C 6 alkoxyC 1 -C 6 alkoxyC 1 -C 3 alkyl; R 2 is hydrogen or C 1 -C 6 alkyl; L is a three atom linkage selected from —CH 2 —X—CH 2 — and —CH 2 —CH 2 —X— where the right hand side of the linkage is attached to R 3 and where X is oxygen, sulfur or methylene; R 3 is phenyl or aromatic heterocyclyl, either of which may be independently substituted by one or more groups selected from: C 1 -C 6 alkyl, halo, haloC 1 -C 6 alkyl, C 1 -C 6 alkoxy, haloC 1 -C 6 alkoxy, C 1 -C 6 alkylthio, haloC 1 -C 6 alkylthio and nitrile; and R 4 and R 5 are either both hydrogen, or one of R 4 and R 5 is hydrogen and the other is a biolabile ester-forming group that in the body of a patient is replaced by hydrogen. |
| priorityDate | 2002-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1239.